...
首页> 外文期刊>In vivo. >The Systemic Immune-Inflammation Index Predicts Clinical Outcomes in Kidney Transplant Recipients
【24h】

The Systemic Immune-Inflammation Index Predicts Clinical Outcomes in Kidney Transplant Recipients

机译:全身免疫炎症指数预测肾移植受者的临床结果

获取原文
           

摘要

BACKGROUND:Outcomes after kidney transplantation (KTx) remain limited by delayed graft function (DGF) and acute rejection. Non-invasive biomarkers may help identify patients at increased risk for these events. We examined the association between the systemic immune-inflammation index (SII), a novel inflammatory biomarker, and outcomes after KTx and evaluated its ability to predict post-transplant prognosis.PATIENTS AND METHODS:Adult patients who underwent primary KTx at our institution between 2016-2019 were included. SII was calculated from pre-transplant complete blood counts as the ratio of the neutrophil count to the lymphocyte count multiplied by the platelet count. The cutoff between high and low SII was determined by maximizing the area under the curve. Multivariable logistic and Cox regression were used to identify factors associated with DGF and patient, rejection-free, and graft survival respectively.RESULTS:Overall, 378 KTx recipients were included; 224 (59.3%) had high SII. On unadjusted analysis, high SII was associated with reduced odds of DGF, and improved patient and rejection-free survival. After adjustment, high SII was independently associated with improved patient survival alone. Multivariable models incorporating SII performed well for the prediction of DGF (c-statistic=0.755) and patient survival (c-statistic=0.786), though rejection-free survival was more difficult to predict (c-statistic=0.635).CONCLUSION:SII demonstrated limited utility as an independent predictor of outcomes after KTx. However, in combination with other clinically relevant parameters, SII is a useful predictor of post-KTx prognosis. Validation of this novel inflammatory biomarker in a multi-institutional study is needed to further elucidate its practical applications in transplantation.Copyright? 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
机译:背景:肾移植(KTX)后的结果仍然受到延迟接枝函数(DGF)和急性排斥的限制。非侵入性生物标志物可以帮助识别这些事件的风险增加的患者。我们检查了KTX后全身免疫炎症指数(SII),新型炎症生物标志物和结果之间的关联,并评估了预测移植后预后的能力:患者和方法:成人患者在2016年间在我们的机构接受初级KTX -2019包括在内。从移植前的完全血液计数计算SiI,因为中性粒细胞计数与血小板计数的比率乘以血小板计数。通过最大化曲线下的区域来确定高和低SII之间的截止。多变量逻辑和Cox回归分别用于分别识别与DGF和患者,拒绝和移植物存活相关的因素。结果:总体而言,包括378 ktx接受者; 224(59.3%)有高Sii。在不调整的分析上,高SiI与DGF的几率降低,改善了患者和不排斥的存活率。调整后,单独单独地与改善的患者存活的高SiI独立相关。掺入SII的多变量模型对DGF的预测(C&Z Qualistic = 0.755)和患者存活(C-Statistic = 0.786)进行了良好的,尽管无抑制存活率更难以预测(C-Statistic = 0.635)。结论:SII在KTX后显示有限的效用作为结果的独立预测因子。然而,与其他临床相关参数组合,SII是KTX后预后的有用预测因子。需要在多机构研究中验证这种新型炎症生物标志物,以进一步阐明其在移植中的实际应用。 2020年,国际抗癌研究所(George J. Delinasios博士),保留所有权利。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号